Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 8, 2013, Pages 1368-1374

  Gupta, Vinod H ^a   Amarapurkar, Deepak N ^b   Singh, Meenakshi ^a   Sasi, Preetha ^a   Joshi, Jyotsna M ^c   Baijal, Rajiv ^d   Ramegowda, Praveenkumar H ^d   Amarapurkar, Anjali D ^e   Joshi, Kalpana ^f   Wangikar, Pramod P ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^b BOMBAY HOSPITAL   (India)

^c BYL Nair Hospital   (India)

^d Jagjivan Ram Western Railway Hospital   (India)

^e BYL NAIR CHARITABLE HOSPITAL   (India)

^f SYMBIOSIS INTERNATIONAL DEEMED UNIVERSITY   (India)

Author keywords

Drug induced hepatotoxicity; Genetic polymorphisms; Slow acetylator; TB patients

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 2E1; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ACETYLATOR PHENOTYPE; ADULT; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; INDIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOSIS;

EID: 84880673426     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12194     Document Type: Article

References (46)

1. Chauhan LS, Tonsing J. Revised national TB control programme in India. Tuberculosis (Edinb.) 2005; 85: 271-276.
2. WHO. Global tuberculosis control 2011. 2012. Geneva, Switzerland. Cited 24 Aug 2012. Available from URL: http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf
3. Joshi JM. Tuberculosis chemotherapy in the 21 century: back to the basics. Lung India 2012; 28: 193-200.
4. Agal S, Baijal R, Pramanik S etal. Monitoring and management of antituberculosis drug induced hepatotoxicity. J. Gastroenterol. Hepatol. 2005; 20: 1745-1752.
5. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J. Gastroenterol. Hepatol. 2008; 23: 192-202.
6. Mitchell JR, Thorgeirsson UP, Black M etal. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin. Pharmacol. Ther. 1975; 18: 70-79.
7. Nelson SD, Mitchell JR, Timbrell JA, Snodgrass WR, Corcoran GB, 3rd. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science 1976; 193: 901-903.
8. Singh M, Sasi P, Rai G, Gupta VH, Amarapurkar D, Wangikar PP. Studies on toxicity of antitubercular drugs namely isoniazid, rifampicin, and pyrazinamide in an in vitro model of HepG2 cell line. Med. Chem. Res. 2011; 20: 1611-1615.
9. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51: 132-136.
10. Chamorro JG, Castagnino JP, Musella RM etal. Sex, ethnicity and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J. Gastroenterol. Hepatol. 2012; 28: 323-328.
11. Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann. Pharmacother. 2004; 38: 1074-1079.
12. Wong WM, Wu PC, Yuen MF etal. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31: 201-206.
13. Ungo JR, Jones D, Ashkin D etal. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am. J. Respir. Crit. Care Med. 1998; 157: 1871-1876.
14. Dossing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber. Lung Dis. 1996; 77: 335-340.
15. Cho HJ, Koh WJ, Ryu YJ etal. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb.) 2007; 87: 551-556.
16. Bose PD, Sarma MP, Medhi S, Das BC, Husain SA, Kar P. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J. Gastroenterol. Hepatol. 2011; 26: 312-318.
17. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am. J. Respir. Crit. Care Med. 2002; 166: 916-919.
18. Leiro V, Fernandez-Villar A, Valverde D etal. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int. 2008; 28: 835-839.
19. Zang Y, Doll MA, Zhao S, States JC, Hein DW. Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis 2007; 28: 1665-1671.
20. Higuchi N, Tahara N, Yanagihara K etal. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J. Gastroenterol. 2007; 13: 6003-6008.
21. Shimizu Y, Dobashi K, Mita Y etal. DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity. Tuberculosis (Edinb.) 2006; 86: 374-381.
22. Ben Mahmoud L, Ghozzi H, Kamoun A etal. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis. Pathol. Biol. (Paris) 2011; 60: 324-330.
23. An HR, Wu UQ, Wang ZY, Zhang JX, Liang Y. NAT 2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin. Exp. Pharmacol. Physiol. 2012; 39: 535-543.
24. Lee SW, Chung LS, Huang HH, Chuang TY, Liou YH, Wu LS. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int. J. Tuberc. Lung Dis. 2010; 14: 622-626.
25. Stephens EA, Taylor JA, Kaplan N etal. Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 1994; 4: 185-192.
26. Vuilleumier N, Rossier MF, Chiappe A etal. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur. J. Clin. Pharmacol. 2006; 62: 423-429.
27. Roy B, Ghosh SK, Sutradhar D, Sikdar N, Mazumder S, Barman S. Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patients. J. Gastroenterol. Hepatol. 2006; 21: 784-786.
28. Liu R, Yin LH, Pu YP. Association of combined CYP2E1 gene polymorphism with the risk for esophageal squamous cell carcinoma in Huai'an population, China. Chin. Med. J. (Engl.) 2007; 120: 1797-1802.
29. Narang A, Jha P, Rawat V etal. Recent admixture in an Indian population of African ancestry. Am. J. Hum. Genet. 2011; 89: 111-120.
30. Malhotra KC. Morphological composition of the people of India. J. Hum. Evol. 1978; 7: 45-53.
31. Helsinki WMADo. Ethical principles for medical research involving human subjects. Bull. World Health Organ. 2001; 79: 373-374.
32. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J. Hepatol. 1990; 11: 272-276.
33. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16: 1215.
34. Doll MA, Fretland AJ, Deitz AC, Hein DW. Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification. Anal. Biochem. 1995; 231: 413-420.
35. Parkin DP, Vandenplas S, Botha FJ etal. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 1997; 155: 1717-1722.
36. R Development Core Team. R: a language and environment for statistical computing. 2011. Vienna, Austria ISBN 3-900051-07-0. Cited 7 Aug 2011. Available from URL: http://www.ats.ucla.edu/stat/r/dac/logit.html
37. Tostmann A, Boeree MJ, Peters WH etal. Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity. Int. J. Antimicrob. Agents 2008; 31: 577-580.
38. Timbrell JA, Wright JM, Baillie TA. Monoacetylhydrazine as a metabolite of isoniazid in man. Clin. Pharmacol. Ther. 1977; 22: 602-608.
39. Ohno M, Yamaguchi I, Yamamoto I etal. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung Dis. 2000; 4: 256-261.
40. Sun F, Chen Y, Xiang Y, Zhan S. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int. J. Tuberc. Lung Dis. 2008; 12: 994-1002.
41. Cai Y, Yi J, Zhou C, Shen X. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS ONE 2012; 7. doi: 10.1371/journal.pone.0047769
42. Lv X, Tang S, Xia Y etal. NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population. Ann. Hepatol. 2012; 11: 700-707.
43. Yamamoto T, Suou T, Hirayama C. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 1986; 6: 295-298.
44. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J. Biochem. 1991; 110: 559-565.
45. Singh J, Arora A, Garg PK, Thakur VS, Pande JN, Tandon RK. Antituberculosis treatment-induced hepatotoxicity: role of predictive factors. Postgrad. Med. J. 1995; 71: 359-362.
46. Huang YS, Chern HD, Su WJ etal. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-930.